KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBITDA (2016 - 2025)

Historic EBITDA for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to -$15.4 million.

  • Fulgent Genetics' EBITDA rose 1012.35% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.0 million, marking a year-over-year increase of 6601.64%. This contributed to the annual value of -$73.9 million for FY2024, which is 6219.59% up from last year.
  • Per Fulgent Genetics' latest filing, its EBITDA stood at -$15.4 million for Q3 2025, which was up 1012.35% from -$19.7 million recorded in Q2 2025.
  • In the past 5 years, Fulgent Genetics' EBITDA ranged from a high of $266.9 million in Q1 2021 and a low of -$151.1 million during Q4 2023
  • In the last 5 years, Fulgent Genetics' EBITDA had a median value of -$16.1 million in 2024 and averaged $27.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 1404576.8% in 2021, then tumbled by 808084.11% in 2024.
  • Quarter analysis of 5 years shows Fulgent Genetics' EBITDA stood at $150.9 million in 2021, then plummeted by 124.23% to -$36.6 million in 2022, then plummeted by 313.44% to -$151.1 million in 2023, then soared by 89.32% to -$16.1 million in 2024, then increased by 4.87% to -$15.4 million in 2025.
  • Its EBITDA stands at -$15.4 million for Q3 2025, versus -$19.7 million for Q2 2025 and -$19.8 million for Q1 2025.